查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1970839

肾衰竭治疗市场－全球产业规模、份额、趋势、机会与预测：按疗法、最终用途、地区和竞争格局划分，2021-2031年

Renal Failure Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment, By End Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球肾衰竭治疗市场预计将从 2025 年的 1,117.8 亿美元成长到 2031 年的 1,970.5 亿美元，复合年增长率达到 9.91%。

该领域涵盖多种用于治疗急性或慢性肾衰竭的治疗性介入和医疗程序，特别是肾臟移植和透析。市场成长的主要驱动力是全球生活型态相关疾病（如高血压和糖尿病）盛行率的不断上升，这些疾病是末期肾病变的主要病因。此外，老年人口的成长也推动了对长期肾臟替代疗法的需求增加，从而确保了腹膜透析和血液透析两种模式的稳定需求，使其免受市场暂时波动的影响。

市场概览
预测期 2027-2031
市场规模：2025年 1117.8亿美元
市场规模：2031年 1970.5亿美元
复合年增长率：2026-2031年 9.91%
成长最快的细分市场 透析
最大的市场 北美洲

然而，该行业面临一个重大障碍：捐赠器官严重短缺。这严重限制了移植手术的数量，迫使患者依赖昂贵的维持性透析治疗。这种供需失衡严重阻碍了根治性治疗的进行。根据美国国家肾臟基金会的报告，到2024年，美国等待肾臟移植的人数将达到90,323人，凸显了器官供应与日益增长的治疗需求之间的巨大差距。

市场驱动因素

全球高血压和糖尿病盛行率的上升是肾衰竭治疗市场的主要驱动因素，直接增加了需要长期照护的人。随着都市化和久坐生活方式的日益普及，这些慢性疾病的盛行率正在加速慢性肾臟病(CKD) 向末期肾功能衰竭(ESRD) 的进展，从而需要即时治疗性介入。患者数量的持续增长反映在主要医疗服务提供者的运作指标中，凸显了对肾臟护理的巨大需求。例如，DaVita 在 2025 年 2 月发布的 2024 年第四季财报中报告称，其服务了约 281,100 名透析患者，这表明医疗保健系统面临巨大压力。同样，医疗照护)报告的透析治疗数量也印证了这一需求的规模，该公司在 2024 年于全球范围内进行了约 4800 万例透析治疗。

同时，以改善病患生活品质为优先的科技进步和临床方法正在推动居家透析疗法的普及，重塑市场格局。远端监测系统和携带式透析设备的创新使居家治疗成为机构治疗之外一种切实可行的更佳选择，从而提高了患者的自主性并降低了感染风险。这种转变为灵活治疗方案的结构性趋势得到了长期数据的支持。根据医学教育研究所于2025年1月发布的《基于2024年美国肾臟资料系统年度资料的居家透析趋势报告》，在分析期间，使用居家血液透析的患者比例增加了60%。为了抓住这一不断增长的市场机会，製造商正在迅速开发便捷易用的居家血液透析和腹膜透析解决方案。

市场挑战

器官捐赠者严重短缺严重阻碍因素全球肾衰竭治疗市场的发展，限制了可进行的移植手术数量。这种短缺阻碍了外科手术领域的扩张，并限制了移植后治疗（市场价值链的关键组成部分）的引入。由于器官供应对肾病发病率的上升缺乏弹性，医疗机构无法扩大根治性手术的规模以满足患者的需求。这种实际的限製造成了瓶颈，导致市场无法充分利用对永久性肾臟替代疗法的需求。

因此，供需严重失衡导致等待时间延长，并使治疗体系内的患者流动停滞不前。根据美国器官共用网路（UNOS）2024年的数据，上年度美国仅进行了约27,000例肾臟移植手术，仅满足了总需求的一小部分。这种限制迫使患者继续依赖维持性透析，阻碍了移植领域的发展，并妨碍了根治性治疗的广泛应用。

市场趋势

GLP-1促效剂和SGLT2抑制剂的临床应用不断扩展，正从根本上改变治疗格局，将治疗重点从肾臟替代疗法转向延缓疾病进展。这一趋势的特点是，能够降低第2型糖尿病合併慢性肾臟病（CKD）患者肾损伤风险的药物疗法已被广泛应用。随着临床指引不断发展，更加重视器官保护，这些治疗方法的处方笺激增，有效拓展了潜在市场，使其超越了传统的血液透析患者群体。这一转变得益于该领域强劲的财务表现。根据《製药技术》（Pharmaceutical Technology）2025年8月刊的报导《诺和诺德的糖尿病和减重药物销售增长放缓》，该公司糖尿病和肥胖症治疗产品组合（包括关键的肾臟保护药物）的销售额在2025年上半年增长了16%，达到1454亿丹麦克朗。

同时，人工智慧（AI）在肾功能预测分析的应用，正透过数据驱动的风险评估和早期疗育策略，变革病患管理模式。医疗机构正日益采用AI驱动的诊断平台来识别高风险患者并优化治疗路径，从而降低紧急透析的发生率。数位诊断工具报销机制的改进加速了这项技术的普及，为临床实践中的应用提供了奖励。近期揭露的财务数据也印证了这些先进分析解决方案日益增长的商业性可行性。根据Renalistics公司截至2025年3月的财年半年报，其商业保险覆盖的检测收入较上年度同期增长28%，反映出预后检测在临床实践中的应用日益广泛。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球肾衰竭治疗市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 治疗方法（透析、肾臟移植、药物治疗、其他）
    • 依最终用途（医院、专科诊所、其他）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美肾衰竭治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲肾衰竭治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区肾衰竭治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲肾衰竭治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲肾衰竭治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章 全球肾衰竭治疗市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • NIPRO
  • Fresenius Medical Care Holdings, Inc
  • Baxter International, Inc
  • Medtronic Plc
  • B. Braun SE
  • Asahi Kasei Medical Co., Ltd.
  • AbbVie Inc.
  • JMS Co.Ltd
  • Nikkiso Co., Ltd
  • AstraZeneca Plc

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 25375

The Global Renal Failure Treatment Market is projected to expand from USD 111.78 Billion in 2025 to USD 197.05 Billion by 2031, achieving a compound annual growth rate of 9.91%. This sector encompasses various therapeutic interventions and medical procedures, specifically kidney transplantation and dialysis, which are employed to manage acute or chronic renal function loss. The market's growth is fundamentally fueled by the increasing global prevalence of lifestyle-associated conditions, such as hypertension and diabetes, which are the leading causes of end-stage renal disease. Additionally, the rising geriatric demographic demands greater access to long-term renal replacement therapies, ensuring a steady demand for both peritoneal dialysis and hemodialysis modalities regardless of temporary market fluctuations.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 111.78 Billion
Market Size 2031USD 197.05 Billion
CAGR 2026-20319.91%
Fastest Growing SegmentDialysis
Largest MarketNorth America

However, the industry confronts a significant obstacle regarding the critical scarcity of donor organs, which severely curtails the volume of transplant surgeries and necessitates a dependence on expensive maintenance dialysis. This imbalance between supply and demand creates a major bottleneck in delivering definitive curative care. As reported by the National Kidney Foundation, there were 90,323 patients on the kidney transplant waiting list in the United States in 2024, highlighting the profound disparity between organ availability and the escalating number of patients requiring treatment.

Market Driver

The rising global incidence of hypertension and diabetes serves as the primary catalyst for the renal failure treatment market, directly increasing the population requiring long-term care. As urbanization and sedentary lifestyles become more widespread, the prevalence of these chronic conditions accelerates the progression from Chronic Kidney Disease (CKD) to End-Stage Renal Disease (ESRD), requiring immediate therapeutic action. This continuous stream of patients is reflected in the operational metrics of major providers, underscoring the substantial demand for renal therapies. For instance, DaVita Inc. reported in their '4th Quarter 2024 Results' in February 2025 that they served approximately 281,100 dialysis patients, demonstrating the heavy burden on healthcare systems. Similarly, the scale of this demand is evident in the procedure volumes reported by Fresenius Medical Care, which performed around 48 million dialysis treatments globally in 2024.

Concurrently, the market is being reshaped by the increasing adoption of home-based dialysis modalities, driven by technological advancements and a clinical focus on improving patient quality of life. Innovations in remote monitoring systems and portable dialysis machines have made home treatment a practical and often preferred alternative to in-center care, offering patients greater independence and lower infection risks. Longitudinal data supports this structural shift toward flexible treatment options; according to the Medical Education Institute's January 2025 'Home Dialysis Updates from the 2024 USRDS Annual Data Report', the proportion of prevalent patients utilizing home hemodialysis grew by 60% during the analyzed period. Consequently, manufacturers are fast-tracking the development of user-friendly home hemodialysis and peritoneal solutions to capitalize on this expanding segment.

Market Challenge

The critical shortage of donor organs functions as a major restraint on the global renal failure treatment market by capping the volume of transplant procedures that can be performed. This scarcity limits the expansion of the surgical segment and restricts the uptake of post-transplant therapies, which are vital components of the market value chain. Because the supply of organs is inelastic compared to the rising incidence of renal disease, healthcare providers are unable to scale curative operations to meet patient needs. This physical limitation generates a bottleneck that prevents the market from fully capitalizing on the demand for permanent renal replacement solutions.

Consequently, the severe gap between supply and demand results in extended waiting periods that stall patient movement through the treatment ecosystem. Data from the United Network for Organ Sharing in 2024 revealed that only approximately 27,000 kidney transplants were performed in the United States during the preceding year, covering a small fraction of the total requirement. This limitation forces a continued dependence on maintenance dialysis, thereby hampering the growth of the transplant sector and stifling the potential for broader adoption of definitive curative treatments.

Market Trends

The expanded clinical application of GLP-1 agonists and SGLT2 inhibitors is fundamentally altering the treatment landscape by shifting focus from renal replacement to delaying disease progression. This trend is characterized by the widespread adoption of pharmaceutical interventions that mitigate the risk of adverse renal outcomes in patients with Type 2 diabetes and Chronic Kidney Disease (CKD). The market is seeing a surge in prescriptions for these therapies as clinical guidelines evolve to prioritize organ protection, effectively expanding the addressable market beyond traditional dialysis populations. This shift is substantiated by strong financial performance in the segment; according to Pharmaceutical Technology in August 2025, in the 'Novo Nordisk's diabetes and weight loss drug sales growth decelerates' article, sales for the company's diabetes and obesity care portfolio, which includes key renal-protective agents, grew 16% to DKK 145.4 billion in the first half of 2025.

Simultaneously, the integration of artificial intelligence for predictive renal analytics is transforming patient management through data-driven risk assessment and early intervention strategies. Healthcare providers are increasingly deploying AI-enabled diagnostic platforms to identify high-risk patients and optimize care pathways, thereby reducing the incidence of emergency dialysis starts. This technological adoption is being accelerated by improved reimbursement structures for digital diagnostic tools, which incentivizes clinical uptake. The growing commercial viability of these advanced analytics solutions is evident in recent financial disclosures; according to Renalytix plc's March 2025 'Half Year Report', the company recorded that commercial insurance reimbursed testing revenue increased by 28% compared to the first half of the previous fiscal year, reflecting the rising utilization of prognostic testing in clinical practice.

Key Market Players

  • NIPRO
  • Fresenius Medical Care Holdings, Inc
  • Baxter International, Inc
  • Medtronic Plc
  • B. Braun SE
  • Asahi Kasei Medical Co., Ltd.
  • AbbVie Inc.
  • JMS Co.Ltd
  • Nikkiso Co., Ltd
  • AstraZeneca Plc

Report Scope

In this report, the Global Renal Failure Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Renal Failure Treatment Market, By Treatment

  • Dialysis
  • Kidney Transplantation
  • Drug Therapy
  • Others

Renal Failure Treatment Market, By End Use

  • Hospitals
  • Specialty Clinics
  • Others

Renal Failure Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Renal Failure Treatment Market.

Available Customizations:

Global Renal Failure Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Renal Failure Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment (Dialysis, Kidney Transplantation, Drug Therapy, Others)
    • 5.2.2. By End Use (Hospitals, Specialty Clinics, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Renal Failure Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Renal Failure Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment
        • 6.3.1.2.2. By End Use
    • 6.3.2. Canada Renal Failure Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment
        • 6.3.2.2.2. By End Use
    • 6.3.3. Mexico Renal Failure Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment
        • 6.3.3.2.2. By End Use

7. Europe Renal Failure Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Renal Failure Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment
        • 7.3.1.2.2. By End Use
    • 7.3.2. France Renal Failure Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Renal Failure Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Renal Failure Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Renal Failure Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment
        • 7.3.5.2.2. By End Use

8. Asia Pacific Renal Failure Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Renal Failure Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Renal Failure Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment
        • 8.3.2.2.2. By End Use
    • 8.3.3. Japan Renal Failure Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment
        • 8.3.3.2.2. By End Use
    • 8.3.4. South Korea Renal Failure Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Renal Failure Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment
        • 8.3.5.2.2. By End Use

9. Middle East & Africa Renal Failure Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Renal Failure Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment
        • 9.3.1.2.2. By End Use
    • 9.3.2. UAE Renal Failure Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment
        • 9.3.2.2.2. By End Use
    • 9.3.3. South Africa Renal Failure Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment
        • 9.3.3.2.2. By End Use

10. South America Renal Failure Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Renal Failure Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment
        • 10.3.1.2.2. By End Use
    • 10.3.2. Colombia Renal Failure Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment
        • 10.3.2.2.2. By End Use
    • 10.3.3. Argentina Renal Failure Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Renal Failure Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. NIPRO
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Fresenius Medical Care Holdings, Inc
  • 15.3. Baxter International, Inc
  • 15.4. Medtronic Plc
  • 15.5. B. Braun SE
  • 15.6. Asahi Kasei Medical Co., Ltd.
  • 15.7. AbbVie Inc.
  • 15.8. JMS Co.Ltd
  • 15.9. Nikkiso Co., Ltd
  • 15.10. AstraZeneca Plc

16. Strategic Recommendations

17. About Us & Disclaimer